Richard-Davis Gloria, Ajmera Mayank, Shiozawa Aki, Doshi Riddhi, Young Christopher, Yeaw Jason, Mancuso Shayna
University of Arkansas Medical Sciences, Little Rock, Arkansas, USA.
Astellas Pharma Inc., Northbrook, Illinois, USA.
J Womens Health (Larchmt). 2025 Jan;34(2):176-186. doi: 10.1089/jwh.2024.0079. Epub 2024 Nov 26.
To estimate the prevalence of diagnosed vasomotor symptoms (VMS) due to menopause among US women aged 40-64 years and assess sociodemographic differences in VMS prevalence and risk of discontinuing VMS-related treatment. This retrospective study evaluated merged data from IQVIA's PharMetrics Plus medical claims and consumer attributes databases for 2017-2020. VMS diagnosis was identified using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes. Continuous enrollment was required ≥6 months before and 12 months after diagnosis date. Treatment discontinuation was measured for VMS-related treatments initiated at diagnosis or during the 12 months after diagnosis. Treatment duration was measured from diagnosis to the first day of a ≥90-day treatment gap. A Cox proportional hazards model was used to determine factors associated with risk of treatment discontinuation. Among 7,386,206 eligible women, the 4-year prevalence of diagnosed VMS in 2017-2020 was 79.1 per 1,000 and was highest among non-Hispanic White women (82.5 per 1,000), followed by Hispanic (77.3), Black (71.6), and Asian women (64.5). Rates were higher among women living in urban areas and those with higher education and income. Among women newly diagnosed with VMS ( = 226,262), median treatment duration was 297 days. Black, Asian, and Hispanic women had higher risks of discontinuing treatment than non-Hispanic White women. Lower income was also associated with higher risk of discontinuation than higher income. Lower prevalence of diagnosed VMS and higher risk of treatment discontinuation were observed among racial/ethnic minorities and women with less education and income, suggesting possible underdiagnosis and unmet needs.
评估美国40 - 64岁女性中因更年期诊断出的血管舒缩症状（VMS）的患病率，并评估VMS患病率及停止VMS相关治疗风险的社会人口学差异。这项回顾性研究评估了IQVIA公司PharMetrics Plus医疗理赔和消费者属性数据库2017 - 2020年的合并数据。使用国际疾病分类第十版临床修订本（ICD - 10 - CM）诊断代码确定VMS诊断。诊断日期前≥6个月及诊断日期后12个月需要持续入组。对诊断时或诊断后12个月内开始的VMS相关治疗进行治疗中断情况的测量。治疗持续时间从诊断到≥90天治疗间隔的第一天进行测量。使用Cox比例风险模型确定与治疗中断风险相关的因素。在7386206名符合条件的女性中，2017 - 2020年诊断出的VMS的4年患病率为每1000人中有79.1例，在非西班牙裔白人女性中最高（每1000人中有82.5例），其次是西班牙裔（77.3）、黑人（71.6）和亚洲女性（64.5）。城市地区女性以及受教育程度和收入较高的女性患病率更高。在新诊断为VMS的女性（n = 22626）中，中位治疗持续时间为297天。黑人、亚洲人和西班牙裔女性比非西班牙裔白人女性有更高的治疗中断风险。低收入者比高收入者也有更高的中断风险。在种族/族裔少数群体以及受教育程度和收入较低的女性中，观察到诊断出的VMS患病率较低且治疗中断风险较高，这表明可能存在诊断不足和未满足的需求。
